Convalescent Plasma Therapy on Critically-ill Novel Coronavirus (COVID-19) Patients
Status:
Completed
Trial end date:
2020-06-01
Target enrollment:
Participant gender:
Summary
Out of 49 early-stage critically-ill COVID-19 patients, 21 patients are the experimental
group who take convalescent plasma compared to 28 patients receive only conventional therapy
without taking Convalescent plasma. Recovery or death, length of stay in hospital, and
improvement in the clinical course of the disease are monitored in relation to monitoring
through severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) RNA detection via poly
chain reaction (PCR), and SARS-CoV-2 immunoglobulin G (IgG) and immunoglobulin M (IgM)
serological monitoring.